Investigation of a Family with Autosomal Dominant Dilated Cardiomyopathy Defines a Novel Locus on Chromosome 2q14-q22  by Jung, Martin et al.
Am. J. Hum. Genet. 65:1068–1077, 1999
1068
Investigation of a Family with Autosomal Dominant Dilated
Cardiomyopathy Defines a Novel Locus on Chromosome 2q14-q22
Martin Jung,1 Imke Poepping,2 Andreas Perrot,2 Annette E. Ellmer,2 Thomas F. Wienker,1,*
Rainer Dietz,2 Andre´ Reis,1,3 and Karl Josef Osterziel2
1Mikrosatellitenzentrum, Max-Delbru¨ck-Centrum, 2Franz-Volhard-Klinik, Charite´, Humboldt University, and 3Institut fu¨r Humangenetik,
Charite´, Humboldt University, Berlin
Summary
Dilated cardiomyopathy (DCM) is a leading cause of
heart failure and the most frequent indication for heart
transplantation in young patients. Probably 125% of
DCM cases are of familial etiology. We report here ge-
netic localization in a three-generation German family
with 12 affected individuals with autosomal dominant
familial DCM characterized by ventricular dilatation,
impaired systolic function, and conduction disease. After
exclusion of known DCM loci, we performed a whole-
genome screen and detected linkage of DCM to chro-
mosome 2q14-q22. Investigation of only affected indi-
viduals defines a 24-cM interval between markers
D2S2224 and D2S2324; when unaffected individuals
are also included, the critical region decreases to 11 cM
between markers D2S2224 and D2S112, with a peak
LOD score of 3.73 at recombination fraction 0 at
D2S2339. The identification of an additional locus for
familial autosomal dominant DCM underlines the ge-
netic heterogeneity and may assist in the elucidation of
the causes of this disease.
Introduction
Dilated cardiomyopathy (DCM) (MIM 102540, MIM
115200, MIM 212110, MIM 300069, MIM 302045,
MIM 302060, MIM 510000, MIM 600884, MIM
601154, MIM 601493, MIM 601494, and MIM
602067) is a heart-muscle disease characterized by ven-
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tricular dilatation and impaired systolic function. The
incidence of DCM is 7/100,000 per year, and the prev-
alence is 37/100,000 (Codd et al. 1989; Rakar et al.
1997). DCM is a leading cause of heart failure and the
most frequent indication for heart transplantation in
young patients (Dec and Fuster 1994). Heart failure is
a progressive clinical syndrome, with a median survival
time of 1.7 years in men and 3.2 years in women (Ho
et al. 1993). Most patients die from pump failure or
sudden cardiac death.
Although familial occurrence of DCM has been re-
ported for the first time by Whitfield (1961), the fre-
quency of familial etiology has been systematically ex-
amined only recently (Mestroni and Giacca 1997).
Systematic examination of relatives showed that prob-
ably 125% of DCM cases are of familial etiology (Mich-
els et al. 1992; Keeling et al. 1995; Gru¨nig et al. 1998).
The mode of inheritance in most families seems to be
autosomal dominant (Michels et al. 1992), but auto-
somal recessive, X-linked, and mitochondrial transmis-
sion have also been reported (Mestroni and Giacca
1997).
To date, three genes—two X-linked genes (dystrophin
and tafazzin) and cardiac actin—have been identified as
causes of DCM (Muntoni et al. 1993; Bione et al. 1996;
D’Adamo et al. 1997; Olson et al. 1998). Mutations in
the dystrophin gene (Xp21) in males lead to early man-
ifestation of DCM, at age of 15–21 years and to rapid
progression to death, usually after !1 year, whereas af-
fected females present with mild symptoms of heart fail-
ure during the 5th and 6th decade, with a gradual decline
of cardiac function (Berko and Swift 1987; Muntoni et
al. 1993; Towbin et al. 1993). The infantile X-linked
DCM is caused by mutations of the tafazzin gene (G4.5
gene; Xq28) (Bione et al. 1996; D’Adamo et al. 1997).
The function of tafazzin is unknown. The onset of the
disease is typically during the 1st year of life, and death
usually occurs during childhood. In addition, most pa-
tients may be characterized by skeletal myopathy, short
stature, neutropenia, and abnormal mitochondria, also
referred to as “Barth syndrome” (Neustein et al. 1979;
Barth et al. 1983; D’Adamo et al. 1997). The only
Figure 1 Pedigree of family with autosomal dominant DCM, with most likely marker haplotypes from the linked region on chromosome 2q. Key recombination events were observed with
marker D2S2224, in individual 004; with marker D2S112, in individual 003; and with marker D2S2324, in individual 010.
Table 1
Evaluation of Clinical Data
HEIGHT
(cm)
WEIGHT
(kg) SYMPTOM(S)a RHYTHMb
24-h
HOLTER
ECGc
PM/
AICDd
LV
FSe
(%)
LV-EFf
AND NO
CAD
TOTAL
POINTSg
AFFECTION
STATUS
INTERVAL
Diameter
(mm)
Dilatation
Global
Hypo-
kinesiah
INDIVIDUAL
AGE ( [years])
HR
(1/min)
PR
(ms)
QRS
(ms)
End
Diastolic
End
Systolic
1.1 (53i) 167 45 ) 1AVB() 1 Absent
1.2 (55i) 172 57 ) Presentj 4 Affected
2.2 (36i) ) ) NYHA II, palpitations SB, 1AVB() 50 200 !110 ) DDD 57 ) Present Present ) NDk 12 Affected
001 (50i) 172 63 NYHA III, palpitations,
stroke
1AVB(), intermittent
2AVB(), LBBB
86 280 140 SVT AICD 74 68 Present Present 20 12 21 Affected
002 (50) None ) ) ) ) ) ) ) ) ) ) ) ) 0 Unaffected
003 (52) 164 66 None 1AVB() 81 230 80 ) ) 50 30 Absent Absent 40 ) 1 Unaffected
004 (50) ) ) NYHA II, palpitations AF, intermittent SB,
1AVB(), 3AVB()
41 ) !110 UVT ) 52 38 Absent Present 27 ) 13 Affected
005 (46) 168 63 NYHA II–III, palpitations 1A-
VB(), LBBB, inter-
mittent AF
89 250 120 VF AICD 70 60 Present Present 14 25 19 Affected
006 (42) ) ) VBI SB 54 160 90 Absent ) 45 28 Absent Absent 38 ) 1 Unaffected
007 (44) 176 107 NYHA II–III, palpitations 1AVB(), LBBB 72 250 140 SB, UVT AICD 63 47 Present Present 25 20 20 Affected
008 (42) 169 99 None SR 84 120 80 ) ) 55 30 Absent Absent 45 ) 0 Unaffected
010 (35) ) ) NYHA II–III, palpita-
tions, stroke
1AVB(), LBBB 55 260 140 UVT AICD ) ) Present Present ) 48 16 Affected
011 (31) 159 57 None 1AVB() 80 200 80 ) ) 44 31 Absent Absent 30 ) 1 Unaffected
012 (32) 159 58 Palpitations 1AVB() 67 227 90 SVTl ) 52 38 Present Present 27 ) 9 Affected
013 (28) 170 62 None SR 70 160 100 SB ) 52 43 Absent Present 17 ) 5 Affected
014 (23) 171 54 NYHA II SR 70 150 110 SB ) 45 33 Absent Present 27 ) 7 Affected
015 (30) 169 62 None SR 73 140 80 ) ) 48 30 Absent Absent 38 ) 0 Unaffected
016 (24) 168 59 None SR 51 140 90 ) ) 50 32 Absent Absent 36 ) 0 Unaffected
017 (18) 189 81 None SR 81 150 110 ) ) 50 38 Absent Present 24 ) 5 Affected
018 (17) 170 63 None ST 115 120 90 ) ) 50 37 Absent Present 26 ) 5 Affected
020 (13) 150 52 None SR 77 125 90 ) ) 44 24 Absent Absent 45 ) 0 Unaffected
022 (35) 157 55 None SR 75 140 80 ) ) NDm ) Absent Absent Normal ) 0 Unaffected
023 (18) 175 64 None SR 82 180 90 ) ) 50 30 Absent Absent 40 ) 0 Unaffected
024 (17) 167 64 None SR 65 160 90 ) ) 45 28 Absent Absent 38 ) 0 Unaffected
NOTE.—Only abnormal values are documented.
a NYHA = symptoms on exertion, as evaluated on the basis of the New York Heart Association functional classification; palpitations are defined as irregular and fast heart beats;
stroke is as diagnosed by neurologists; VBI = vertebrobasilar ischemia.
b () and () = with and without medication slowing atrioventricular conduction, respectively; SB = sinus bradycardia; LBBB = left bundle-branch block; AF = atrial fibrillation;
SR = sinus rhythm; ST = sinus tachycardia.
c SVT = sustained ventricular tachycardia; UVT = unsustained ventricular tachycardia; VF = ventricular fibrillation; SB = sinus bradycardia; SVT = supraventricular
tachyarrhythmia.
d Pacemaker/automatic cardioverter defibrillator implanted. DDD = pacemaker in DDD mode.
e Fractional shortening, determined by echocardiography. NA = not applicable (since, although LV-EF was significantly decreased, it could not be exactly determined).
f LV dilation and ejection fraction, determined angiographically; CAD absence determined by selective coronary angiography.
g Symptoms and signs scored on the basis of data in table 2.
h Determined by echocardiography or angiography.
i Age at death.
j Biventricular dilation of all cardiac chambers, on autopsy.
k LV-EF significantly decreased but unable to be exactly determined.
l 190/min.
m Not dilated.
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Table 2
Quantitative Phenotype Scoring
Criterion Points
Major:
Dilated left ventricle with reduced ejection fraction and exclusion of CAD, by angiography 4
Dilation of all cardiac chambers, on autopsy 4
LV dilation 195% (corrected for body-surface area) 2
Fractional shortening !28% 2
Global LV hypokinesia 2
2AVB or 3AVB 2
Ventricular tachycardia 2
Pacemaker/automatic cardiac defibrillator implantation 2
Minor:
New York Heart Association classification 12 1
Palpitations 1
Stroke 1
Sinus bradycardia (heart rate !60/min) 1
1AVB, PR 1 200 ms 1
Unexplained supraventricular tachyarrhythmia 1
Unexplained atrial fibrillation 1
Increased QRS duration ( )QRS 1 110 ms 1
Left bundle-branch block ( )QRS 1 120 ms 1
NOTE.—Points were summed up for each individual and then the status of the latter was classified as
unaffected (0 or 1 point), uncertain (2 or 3 points), or affected (4 points).
known gene causing autosomal dominant–transmitted
DCM is the cardiac actin gene (15q14) (Olson et al.
1998). Two different missense mutations in the immo-
bilized end of the actin filament are known to cause the
disease (Olson et al. 1998). Age at onset in the two
families showed a wide range, 1–41 years, and affected
individuals presented with left-ventricular (LV) dilata-
tion and impaired systolic function, without apparent
conduction disease (Olson et al. 1998).
In addition, seven loci for autosomal dominant DCM
have been reported on chromosomes 1p1-q1 (CMD1A),
9q13-q25 (CMD1B), 10q21-q23 (CMD1C), 1q32
(CMD1D), 3p25-p22 (CMD1E), 6q23 (CMD1F), and
2q31 (CMD1G) (Kass et al. 1994; Durand et al. 1995;
Krajinovic et al. 1995; Bowles et al. 1996; Olson and
Keating 1996; Messina et al. 1997; Siu et al. 1999).
CMD1A and CMD1E are characterized by conduction
abnormalities preceding cardiac dilatation and systolic
dysfunction (Kass et al. 1994; Olson and Keating 1996).
The first abnormalities are sinus and/or atrioventricular-
node dysfunction, resulting in sinus bradycardia, pauses
and arrest, first- to third-degree atrioventricular block
(1AVB–3AVB), and/or atrial fibrillation. CMD1F is
also associated with AVB and, in addition, with mild
proximal limb-girdle muscular dystrophy, which can be
recognized initially during the late 3d decade (Messina
et al. 1997). CMD1C is associated with mitral-valve
prolapse in all cases (Bowles et al. 1996). DCM loci at
CMD1B, CMD1D, and CMD1G are not associated with
either conduction disease or skeletal muscular dystrophy
(Durand et al. 1995; Krajinovic et al. 1995; Siu et al.
1999). Although many candidate genes in these loci have
been examined, the responsible genes are yet unknown.
We describe here a novel locus for autosomal dominant
DCM associated with conduction disease (CMD1H), on
chromosome 2q14-q22 in a three-generation German
kindred.
Subjects and Methods
Phenotypic Characterization
After informed consent was obtained in accordance
with the guidelines of the ethical commission of the
Max-Delbru¨ck-Center for Molecular Medicine, clinical
evaluation was performed, and blood samples from a
German family (fig. 1) were drawn in the Franz-Volhard-
Klinik. Family members were evaluated on the basis of
medical history, physical examination, two-dimensional
and M-mode echocardiography, 12-lead electrocardio-
gram, and, in some cases, Holter electrocardiography
(Holter ECG) (table 1). Five affected members had left
ventriculography showing a reduced LV ejection frac-
tion, as determined by the area-length method (Sandler
and Dodge 1968). In each case, coronary-artery disease
(CAD) as a cause of the decreased LV function was ex-
cluded by selective coronary angiography. LV dilatation
was defined as LV end-diastolic diameter 195% for
body-surface area (Henry et al. 1980). Impaired systolic
function was defined as either a shortening fraction of
!28% by M-mode echocardiography or decreased ejec-
tion fraction of !50% (Mestroni et al. 1999). In addi-
tion, global LV hypokinesia as determined by two-di-
mensional echocardiography was taken to be a sign of
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Figure 2 Part of genetic map of human chromosome 2q. The region including the DCM gene is marked. Genetic distances between
markers are given (in cM). Microsatellite loci were obtained from the final Ge´ne´thon linkage map (Dib et al. 1996). The locations of nebulin
(NEB), the disease gene of autosomal recessive nemaline myopathy 2 (NEM2), titin (TTN), and the adjacent CMD1G locus are shown.
DCM. ECG abnormalities were defined according to es-
tablished criteria.
The clinical findings were rated by a point assignment,
without knowledge of genotype (table 2). Affection
status was based on major and minor criteria. Major
criteria were LV dilatation, reduced systolic function,
documented ventricular tachycardias and fibrillation,
implantation of automatic cardioverter defibrillators,
2AVB or 3AVB, or implantation of pacemakers. The
greatest accuracy of diagnosis is achieved by LV angi-
ography and exclusion of CAD and by autopsy. There-
fore, these criteria were assigned the highest-scoring
points. Minor criteria were supraventricular tachyar-
rhythmias, 1AVB, increased QRS duration, left bundle-
branch blocks, symptoms or signs of reduced myocardial
performance, such as dyspnoe on exertion, and signs of
tachyarrhythmias sensed as palpitations. The only other
family study in which DCM was evaluated by a scoring
system did not differentiate between major and minor
criteria and rated non–DCM-specific cardiovascular
events such as stroke at age !40 years as having the
highest-scoring points (Olson and Keating 1996). Re-
cently, Mestroni et al. (1999) have suggested guidelines
for the study of familial DCM. The authors stated that
the complete criteria required for the diagnosis of DCM
appeared to be too restrictive in familial DCM. We there-
fore used slightly different major and minor criteria, all
of which are suggestive of DCM associated with con-
duction abnormalities, in order to obtain a higher sen-
sitivity to detect DCM in the absence of knowledge of
the genotype.
Genotyping
DNA was isolated by standard techniques. Microsat-
ellite markers were from the MDC-Ge´ne´thon microsat-
ellite mapping panel, with an average spacing of 11 cM
(M. Jung, unpublished data). Loci were chosen from the
final Ge´ne´thon linkage map (Dib et al. 1996). Markers
were amplified by simplex PCR on a MJ Tetrad cycler,
were separated on an ABI 377 DNA sequencer, and were
analyzed by GENESCAN version 2.2 and GENO-
TYPER version 2.0 software (ABI). All genotypes were
checked for Mendelian segregation, by LINKRUN (T. F.
Wienker, personal communication). No DNA was avail-
able from individuals 2.1 and 2.2.
Linkage Analysis
Power calculations, prior to genome scan, by the pro-
gram [FAST]SLINK (Weeks et al. 1990) revealed a max-
imum two-point LOD score of 4.14 and an expected
LOD score of 2.24, at recombination fraction (v) .05.
Two-point LOD scores were calculated by the LINK-
AGE-program package (Lathrop and Lalouel 1984),
and, for each chromosome, the exclusion map was dis-
played by LODVIEW, an Microsoft Excel application
(Hildebrandt et al. 1993). Multipoint analyses were per-
formed by VITESSE (O’Connell and Weeks 1995). The
most likely haplotypes were constructed manually.
Since manifestation of DCM is age dependent, pen-
etrance values were modified as follows: 60% for un-
affected individuals 20 years of age (individuals 020,
023, and 024), 90% for those 30 years of age (indi-
viduals 015 and 016), those 45 years of age (individ-
uals 006 and 011), and 99% in those 45 years of age
(individual 003). Asymptomatic individuals !30 years
of age who were scored clinically as affected (individuals
013, 014, 017, and 018) were assigned a penetrance
value of 90%, whereas all other affecteds were scored
as fully penetrant.
Results
A total of 25 members of a family with autosomal
dominant inheritance of DCM (fig. 1) were examined in
detail (table 1). On the basis of a scoring system shown
in table 2, patients with 13 points were classified as
affected. Of the 12 individuals who were diagnosed as
affected, 5 had invasive angiography to exclude other
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Table 3
Pairwise LOD Scores between DCM and Markers on Chromosome 2
MARKER
(POSITION [CM]a)
LOD SCORE AT v =
MAXIMUM
LOD SCORE
MAXIMUM
v.0 .01 .05 .1 .2 .3 .4
D2S2254 132.6 5.57 1.67 2.13 2.11 1.72 1.11 .40 2.15 .07
D2S2224 134.6 5.69 1.08 1.57 1.60 1.31 .82 .27 1.61 .08
D2S347 135.7 1.05 1.03 .95 .84 .61 .35 .11 1.08 .00
D2S2339 136.8 3.73 3.67 3.41 3.06 2.32 1.48 .55 3.73 .00
D2S2296 137.4 3.26 3.20 2.95 2.63 1.95 1.20 .40 3.26 .00
D2S112 145.8 1.09 1.76 2.15 2.12 1.72 1.12 .40 2.16 .07
D2S127 154.3 1.73 1.97 2.20 2.14 1.73 1.12 .41 2.20 .06
D2S2313 156.4 1.36 1.34 1.23 1.10 .82 .50 .19 1.36 .00
D2S151 156.4 .71 .70 .63 .55 .38 .23 .09 .71 .00
D2S2324 158.6 5.69 .80 .32 .66 .73 .52 .21 .75 .19
D2S2275 159.4 5.21 .23 .87 1.16 1.12 .77 .29 1.20 0.14
a
a On the genetic map, according to Dib et al. (1996).
causes of ventricular dilatation and impaired LV systolic
function; in all 5 patients, CAD was excluded by selec-
tive coronary angiography, and the diagnosis was con-
firmed in 1 patient by autopsy. A total of 8 family mem-
bers were clinically unaffected. There were no clinical
data available from the deceased individual, 2.1.
The severity of the disease showed great variability in
affected members. Disease manifestation in this family
began during adolescence, with sinus- or atrioventricu-
lar-node dysfunction. Clinical manifestations were sinus
bradycardia, sinus tachycardia, supraventricular tach-
yarrythmias, and/or 1AVB–3AVB. Then intraventri-
cular conduction was delayed, resulting in either pro-
longed QRS duration or left bundle-branch block. In the
early stages, LV systolic function was only mildly de-
creased, but ventricular dilatation could not yet be ob-
served. Later, malignant tachyarrhythmias were re-
corded, leading to implantation of automatic cardio-
verter defibrillators in four of the five living affected
individuals 135 years of age. Both moderate dilatation
of the left atria and ventricles and severe systolic dys-
function occurred as late signs. The end stage of disease
manifested clinically as overt congestive heart failure.
The known loci on chromosome 1p1-q1, 1q32, 3p25-
p22, 6q23, 9q13-q22, and 10q21-q23 and the actin gene
locus on chromosome 15q14 were excluded by linkage
analysis. Then a genomewide screen was initiated, and
a total of 310 microsatellite markers were typed. Ini-
tially, two regions, on chromosomes 9q and 2q, showed,
by two-point analysis, evidence for linkage to DCM.
Haplotype analyses clearly excluded the region on chro-
mosome 9 (data not shown). In contrast, the family was
concordant for a region on 2q14-q22. Recombination
events in only the affected individuals defined a 24-cM
critical region delineated by recombination events, in
individual 004, by marker D2S2224, and in individual
010, by marker D2S2324 (figs. 1 and 2). A further re-
combination event was observed in unaffected individual
003, which reduces the critical region to an 11-cM seg-
ment between markers D2S2224 and D2S112. This in-
dividual was 52 years of age when last seen and had
only 1AVB but otherwise was healthy. Using the scoring
system devised prior to genotyping she was diagnosed
as unaffected. When disease penetrance was assumed to
be 60%–100%, dependent on the age of the individuals,
two-point analyses gave a peak LOD score, for
D2S2339, of 3.73 at (table 3).v = 0
Discussion
We have identified a three-generation family with au-
tosomal dominant DCM and conduction-system disease.
In a genomewide scan for linkage to DCM, we were able
to exclude 190% of the autosomal genome. Two regions
showed evidence for linkage. After haplotype analysis,
the region on chromosome 9 could be excluded (data
not shown). In contrast, the region on chromosome 2q
could be confirmed by both detailed analysis of numer-
ous markers (table 3) and extensive haplotyping (fig. 1).
Linked markers have been assigned to the long arm of
chromosome 2, in the region 2q14-q22.
Clinical symptoms manifest only at a late stage of
DCM. Therefore, linkage mapping is difficult in this late-
onset disease. Sensitive diagnostic procedures are needed
to identify minimal cardiac dysfunction, especially in
younger individuals. On the basis of a scoring system
similar to that suggested by Mestroni et al. (1999), in-
dividuals in this family were classified as either affected
or unaffected. Severe arryhthmias were rated as a major
criterion, since they represent a special feature of the
DCM family described by us. Three other DCM families,
with linkage to 1p1-q1, 3p25-p22, and 6q23, showed a
combination of DCM and sinus- and/or atrioventricular-
node disease (Kass et al. 1994; Olson and Keating 1996;
Jung et al.: Dilated-Cardiomyopathy Locus on Chromosome 2q 1075
Messina et al. 1997) similar to that seen in the family
described here. The bradyarrhyhthmias required im-
plantation of pacemakers in most affected individuals of
the family with CMD1A and in some patients of the
family with CMD1F (Kass et al. 1994; Messina et al.
1997). Only one individual in the family that we studied
received a pacemaker, because of symptomatic AVB. In
contrast to the other three families with DCM and con-
duction disease, 5 of the 12 affected individuals of the
family that we studied had documented ventricular tach-
ycardias, and 4 of them received an automatic cardiov-
erter defibrillator. Clinical overt congestive heart failure
occurred only at an older age (table 1).
Using a conservative approach, which considered af-
fecteds only, we were able to identify, on chromosome
2, a critical region of 24 cM defined by recombination
events in individuals 004 and 010 (fig. 1). When we
consider the unaffected individuals as well, the region
can be reduced to an 11-cM interval, because of a re-
combination event in individual 003. This clinically un-
affected 52-year-old woman shows only 1AVB. Her af-
fected siblings had a much earlier manifestation of the
disease. We therefore scored her as unaffected.
Recently, Siu et al. (1999) have reported mapping of
a DCM locus with early onset and a rapidly progressive
course of the disease and apparently reduced penetrance.
They have identified linkage to markers on chromosome
2q31, distal to the region described in the present study,
and have proposed titin, a giant sarcomeric protein, as
a candidate gene. However, sequence analysis of the car-
diac-specific N2-B domain of titin failed to detect dis-
ease-causing mutations. The clinical manifestation in the
family that we studied is markedly different from that
in the family described by Siu et al. (1999). Affected
members in the family described here are characterized
by early onset of conduction disease, followed by ma-
lignant ventricular arrhythmias and mild ventricular dil-
atation and overt heart failure at later stages. In contrast,
affected individuals described by Siu et al. (1999) are
characterized by early onset of ventricular dilatation and
a rapid progressive deterioration without conduction ab-
normalities. The different clinical manifestation and
course of the disease in both families, considered to-
gether with the different, although adjacent genetic lo-
calization (fig. 2), argues for the existence of two DCM
loci on chromosome 2. Only identification of the disease-
causing mutations will prove this likely assumption.
Disrupted force transmission from the sarcomere to
the extracellular matrix has been suggested as a cause
of DCM (Olson et al. 1998). Structural proteins such as
dystrophin, dystrophin-associated glycoproteins such as
sarcoglycans, muscle LIM, and sarcomeric proteins re-
sponsible for force transmission may therefore be in-
volved in the etiology of DCM. Mutations in dystrophin
cause X-linked DCM in humans (Muntoni et al. 1993;
Milasin et al. 1996), and mutations in -sarcoglycan lead
to DCM in hamsters (Sakamoto et al. 1997). Muscle
LIM knockout in mice also causes DCM (Arber et al.
1997). The giant sarcomeric protein nebulin, which is a
component of the cytoskeletal matrix, is located within
the 24-cM region defined by the affecteds-only model
(fig. 2) (Wallgren-Pettersson et al. 1995). Recently, mu-
tations in this gene have been identified as the cause of
autosomal recessive nemaline myopathy 2, a syndrome
with an increased number of muscle fibers with central
nuclei and rods (Arts et al. 1978; Wallgren-Pettersson et
al. 1988; Pelin et al. 1999). This disorder is characterized
by infantile onset of slowly progressive or nonprogres-
sive weakness of facial and proximal-limb skeletal mus-
cles (Wallgren-Pettersson et al. 1988; Goebel 1998).
Nebulin is apparently not expressed in cardiac tissue
(Schiaffino and Reggiani 1996); therefore, although neb-
ulin is located within the 24-cM critical region, it seems
an unlikely candidate gene for DCM in this family. In
addition, it clearly would be excluded from the 11-cM
region defined by the recombination event in unaffected
individual 003. Titin, the candidate proposed by Siu et
al. (1999) for the disease in the family with CMD1G,
maps outside the critical region defined in the family
described by us. No other obvious candidate gene coding
for cytoskeletal proteins has been mapped to this region.
In summary, we have identified a novel DCM locus
associated with conduction-system disease, on chro-
mosome 2q14-q22. This confirms that DCM is geneti-
cally heterogeneous. Identification of the responsible
gene would improve our understanding of both DCM
and conduction-system disorders in general. Ultimately,
new diagnostic and, it is hoped, therapeutic strategies,
such as genetic reconstitution of the disease gene (Gree-
lish et al. 1999), may evolve from this knowledge.
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